Imara-Logo-Color-RGB.jpg
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
17 mars 2021 07h00 HE | Imara, Inc.
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower...
Imara-Logo-Color-RGB.jpg
Imara Reports Full Year 2020 Financial Results and Business Highlights
05 mars 2021 07h00 HE | Imara, Inc.
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
26 févr. 2021 21h30 HE | Imara, Inc.
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
19 févr. 2021 07h00 HE | Imara, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
20 janv. 2021 07h00 HE | Imara, Inc.
BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
06 janv. 2021 07h00 HE | Imara, Inc.
Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement...
Imara-Logo-Color-RGB.jpg
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
07 déc. 2020 07h00 HE | Imara, Inc.
Preliminary data as of August 2020 from ongoing Phase 2a open label extension trial showed increases in HbF percentage and F-cells after approximately six months of treatment Case reports showed...
Imara-Logo-Color-RGB.jpg
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
30 nov. 2020 07h00 HE | Imara, Inc.
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
17 nov. 2020 07h00 HE | Imara, Inc.
BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
05 nov. 2020 07h00 HE | Imara, Inc.
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...